Sexual Dysfunction in Subjects Treated with Inhibitors of 5α-Reductase for Benign Prostatic Hyperplasia: A Comprehensive Review and Meta-Analysis

    September 2023 in “ International Journal of Andrology
    Giovanni Corona, Giacomo Tirabassi, Daniele Santi, Elisa Maseroli, Mauro Gacci, Mauro Dicuio, Alessandra Sforza, Edoardo Mannucci, Mario Maggi
    Image of study
    TLDR Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
    This comprehensive review and meta-analysis, which included 17 randomized clinical trials with a total of 24,463 subjects receiving 5α-reductase inhibitors (5ARIs) and 22,270 in placebo groups, found that 5ARIs significantly increase the risk of hypoactive sexual desire (HSD) and erectile dysfunction (ED) in men treated for benign prostatic hyperplasia (BPH). The odds ratios were 1.54 for HSD and 1.47 for ED, indicating a substantial increase in risk compared to placebo, with no significant difference between the two drugs, finasteride and dutasteride. The risk was higher in subjects with lower urinary flow rates at the start of the trials and decreased over time. The study concludes that patients should be informed about these risks before starting 5ARI treatment for BPH.
    View this study on onlinelibrary.wiley.com →

    Cited in this study

    13 / results